Insights about the data:

* Capomulin and Ramicane have the most data points
* The amount of male and female mice is similar, therefore differences regarding gender are not relevant at this moment
* Capomulin and Ramicane seem to be more promising drug regimen treatments since the average tumor reduction is higher
* There is an oulier in the Infubinol data set
* Average tumor volume reduces as days of Capomulin treatment increase for mouse l509
* A correlation of 0.84 exists between the average tumor volume and weight in regards to the Capomulin drug regimen